196 related articles for article (PubMed ID: 33579052)
1. A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin.
Xian J; Bu F; Wang Y; Long F; Zhang Z; Wu C; Tao Y; Wang T; Wang G
Molecules; 2021 Feb; 26(4):. PubMed ID: 33579052
[TBL] [Abstract][Full Text] [Related]
2. Microtubules depolymerization caused by the CK1 inhibitor IC261 may be not mediated by CK1 blockage.
Stöter M; Krüger M; Banting G; Henne-Bruns D; Knippschild U
PLoS One; 2014; 9(6):e100090. PubMed ID: 24937750
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
Li Y; Yang J; Niu L; Hu D; Li H; Chen L; Yu Y; Chen Q
FEBS Lett; 2020 Jan; 594(1):199-204. PubMed ID: 31369682
[TBL] [Abstract][Full Text] [Related]
4. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
[TBL] [Abstract][Full Text] [Related]
5. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
Coluccia A; Sabbadin D; Brancale A
Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta.
Höttecke N; Liebeck M; Baumann K; Schubenel R; Winkler E; Steiner H; Schmidt B
Bioorg Med Chem Lett; 2010 May; 20(9):2958-63. PubMed ID: 20350806
[TBL] [Abstract][Full Text] [Related]
7. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
8. Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design.
Niu L; Wang Y; Wang C; Wang Y; Jiang X; Ma L; Wu C; Yu Y; Chen Q
Biochem Biophys Res Commun; 2017 Nov; 493(1):718-722. PubMed ID: 28864414
[TBL] [Abstract][Full Text] [Related]
9. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
10. Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin.
Tyagi C; Gupta A; Goyal S; Dhanjal J; Grover A
BMC Genomics; 2014; 15 Suppl 9(Suppl 9):S3. PubMed ID: 25521775
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
12. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
14. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
[TBL] [Abstract][Full Text] [Related]
15. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
[TBL] [Abstract][Full Text] [Related]
16. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.
Li W; Sun H; Xu S; Zhu Z; Xu J
Future Med Chem; 2017 Oct; 9(15):1765-1794. PubMed ID: 28929799
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
18. Electrostatic contributions to colchicine binding within tubulin isotypes.
Huzil JT; Barakat K; Tuszynski JA
Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of crolibulin in complex with tubulin provides a rationale for drug design.
Zhang Z; Wang C; Ma L; Jiang X; Wu C; Wang Y; Jiang Y; Zheng W; Yang Y; Ma Y; Yang J
Biochem Biophys Res Commun; 2019 Apr; 511(2):381-386. PubMed ID: 30803758
[TBL] [Abstract][Full Text] [Related]
20. Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.
Wang J; Miller DD; Li W
Drug Discov Today; 2022 Mar; 27(3):759-776. PubMed ID: 34890803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
